RareStone’s pitolisant (Wakix) was approved by China NMPA for the treatment of narcolepsy, and became the first approved innovative drug for narcolepsy and the only non-scheduled drug with narcolepsy indication

July 4th, 2023|

Vivo Capital Invests in Zenas Biopharma’s $118 Million Financing to Advance the Company’s Broad Pipeline of Autoimmune Disease Therapeutics

November 7th, 2022|

Ablaze Pharmaceuticals Launches with $75M Series A Financing to Bring Novel Targeted Radiopharmaceuticals to Treat Cancer Patients in the Greater China Market 

November 30th, 2021|

Aadi Bioscience Announces FDA Approval FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)

November 23rd, 2021|
Go to Top